Psychiatry diagnoses and treats mental health conditions, including depression, anxiety, bipolar disorder, and schizophrenia.
Send us all your questions or requests, and our expert team will assist you.
The diagnosis of a Substance Use Disorder is a rigorous clinical process that moves far beyond a simple drug test. Leading psychiatric institutions, such as the Department of Psychiatry at Liv Hospital, employ a multidisciplinary approach that integrates medical, psychological, and sociological data. This comprehensive evaluation is designed to map the severity of the addiction, identify co-occurring disorders, and formulate a personalized treatment strategy.
The process typically begins with a detailed clinical interview. Psychiatrists and clinical psychologists use standardized criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) to assess the presence and severity of the disorder. The criteria focus on four major groupings: impaired control, social impairment, risky use, and pharmacological criteria (tolerance and withdrawal). Meeting two or three criteria indicates a mild disorder, while meeting six or more indicates a severe disorder.
However, modern diagnosis delves deeper. It involves a “Council Evaluation” where experts from various fields—psychiatry, internal medicine, neurology, and sometimes family therapy—collaborate. This team-based assessment ensures that the diagnosis captures the complete picture of the patient’s health, recognizing that addiction affects every organ system and aspect of life.
While patient self-reporting is valuable, it is subjective. Modern psychiatric diagnosis relies heavily on objective biological data provided by Advanced Toxicology Laboratories. These facilities utilize sophisticated technology to detect not just the presence of parent drugs, but also their metabolites, providing a window into the patient’s usage patterns over time.
Beyond detection, biological markers are used to monitor physical health. Tests for blood-borne pathogens (HIV, Hepatitis B, and C) are standard, as are evaluations for nutritional deficiencies (such as Vitamin B1/Thiamine deficiency in alcohol use disorder) and metabolic irregularities. This biological data forms the “baseline” against which physical recovery—or regeneration—is measured.
One of the most significant advancements in psychiatric diagnosis is the integration of genetics. The “one-size-fits-all” approach to treatment is being replaced by Personalized Medicine, driven by phenotype and genotype testing.
This precision medicine approach is particularly relevant in the context of “regenerative” psychiatric care. By aligning treatment with the patient’s specific biological profile, clinicians can optimize the neurochemical environment for brain repair, reducing the trial-and-error period that often leads to treatment drop-out.
A critical component of the evaluation is screening for Dual Diagnosis (or Co-occurring Disorders). Research suggests that a significant percentage of individuals with addiction also suffer from a mental health condition such as depression, bipolar disorder, PTSD, or ADHD. If these underlying conditions are not diagnosed and treated simultaneously, recovery from addiction is unlikely.
The evaluation process includes specialized scales and structured interviews to disentangle symptoms of intoxication/withdrawal from true psychiatric disorders. For example, is the patient’s paranoia a result of methamphetamine use, or is it a sign of underlying schizophrenia? Is the depression a withdrawal symptom, or a pre-existing Major Depressive Disorder? Differentiating these requires skilled longitudinal observation.
Furthermore, the psychosocial evaluation assesses the “recovery capital” of the patient. This includes examining:
Support Systems: Who can the patient rely on during treatment?
In some advanced cases, neuroimaging techniques such as MRI (Magnetic Resonance Imaging) or qEEG (Quantitative Electroencephalogram) may be used to assess brain function and structure. While not continuously routine for every patient, these tools can reveal the extent of “organic” damage caused by substance abuse, such as white matter lesions or reduced activity in the prefrontal cortex.
This “functional” assessment aligns with the regenerative goal. It provides a visual or quantitative representation of the brain’s status, helping to set realistic expectations for cognitive recovery. It underscores the medical reality of the condition to the patient and family, shifting the narrative from blame to biology.
Send us all your questions or requests, and our expert team will assist you.
Dual Diagnosis refers to the coexistence of a substance use disorder and another mental health condition, such as depression or anxiety. It is crucial because the two conditions often interact and worsen each other. Treating only the addiction without addressing the mental health issue (or vice versa) usually leads to relapse. Effective treatment must address both simultaneously.
Genetic testing (pharmacogenomics) helps doctors determine which medications will work best for a specific patient’s body. It reveals how the patient metabolizes drugs, allowing clinicians to prescribe the correct dosage and type of medication (e.g., antidepressants or anti-craving drugs) that will be most effective and have the fewest side effects, thus personalizing the care.
Standard urine tests are generally qualitative, meaning they show “positive” or “negative” for the presence of a drug or its metabolites above a certain threshold. While they indicate that a drug was taken, they are not typically used to measure the exact quantity or dose consumed. Blood tests are more accurate for determining precise concentration levels.
A Council Evaluation is a meeting in which specialists from different medical disciplines (psychiatrists, psychologists, internists, and neurologists) review a patient’s case together. They discuss the medical, psychological, and social aspects of the patient’s condition to ensure a comprehensive diagnosis and to create a unified, multidisciplinary treatment plan.
Yes, patient confidentiality is strictly protected by medical ethics and laws (such as HIPAA in the US or KVKK in Turkey). Information shared during the evaluation, including drug use history and test results, cannot be disclosed to employers, family members (for adults), or legal authorities without the patient’s explicit written consent, except in rare emergencies involving immediate life threats.
